Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential. | Explor Target Antitumor Ther | 2023 | 37455828 | PubTator, text mining | PubMed |
| Global scale phylogeography of functional traits and microdiversity in Prochlorococcus. | ISME J | 2023 | 37454234 | PubTator, text mining | PubMed |
| Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions. | J Transl Med | 2023 | 37452395 | PubTator, text mining | PubMed |
| Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. | Leukemia | 2023 | 37452102 | PubTator, text mining | PubMed |
| Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins. | Mol Cancer Ther | 2023 | 37451822 | PubTator, text mining | PubMed |
| Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma. | Front Immunol | 2023 | 37449207 | PubTator, text mining | PubMed |
| Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling. | CPT Pharmacometrics Syst Pharmacol | 2023 | 37448343 | PubTator, text mining | PubMed |
| Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. | Cancers (Basel) | 2023 | 37444586 | PubTator, text mining | PubMed |
| B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma. | Cancers (Basel) | 2023 | 37444389 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future. | Cells | 2023 | 37443804 | PubTator, text mining | PubMed |
| Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies. | Front Immunol | 2023 | 37441064 | PubTator, text mining | PubMed |
| Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial. | JMIR Res Protoc | 2023 | 37440307 | PubTator, text mining | PubMed |
| Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. | Cancer Immunol Res | 2023 | 37429007 | PubTator, text mining | PubMed |
| Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature. | Ann Med Surg (Lond) | 2023 | 37427200 | PubTator, text mining | PubMed |
| New techniques: a roadmap for the development of HCC immunotherapy. | Front Immunol | 2023 | 37426674 | PubTator, text mining | PubMed |
| Microfluidic Chips: Emerging Technologies for Adoptive Cell Immunotherapy. | Micromachines (Basel) | 2023 | 37421109 | PubTator, text mining | PubMed |
| In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy. | Arch Immunol Ther Exp (Warsz) | 2023 | 37419996 | PubTator, text mining | PubMed |
| Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). | Int J Oncol | 2023 | 37417358 | PubTator, text mining | PubMed |
| Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. | Cell | 2023 | 37413990 | PubTator, text mining | PubMed |
| HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met. | Immunol Invest | 2023 | 37409941 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=26